New York, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Automotive 4D Imaging Radar Market – Global Analysis By Value and Volume, Autonomous Level, Range, ...
4D Molecular Therapeutics (NASDAQ:FDMT), a biotechnology company with a market capitalization of $311 million specializing in gene therapies for wet Age-related Macular Degeneration (wAMD), Diabetic ...
Dublin, Aug. 15, 2023 (GLOBE NEWSWIRE) -- The "4D Printing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides key insights into the 4D ...
4D pharma presents microbiome analyses from Phase II clinical trial of Blautix® for IBS-C and IBS-D at Gastro 2021 Results demonstrate changes in gut microbiome structure following administration of ...
FDMT's lead candidate, 4D-150, is being developed for the treatment of wet AMD, a leading cause of vision loss in older adults. The company has reported data from its Phase 1/2 and 2b PRISM trials, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback